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OVCA 433 human ovarian carcinoma cells treated with 
lxlO"^M dexamethasone exhibit markedly decreased expression 
of CA 125, a nonmucinous, high-molecular weight (M2-=220,000) 
tumor-associated antigen as determined by an indirect 
immunoperoxidase technique with OC 125, a monoclonal 
antibody (MAb) recognizing the CA 125 determinant. 
Inhibition of CA 125 expression parallels dose-dependent 
glucocorticoid-induced effects leading to 32% growth 
inhibition and the appearance of cell morphological 
alterations, including enlargement, rounding, flattening, 
and multinucleation. CA 125 inhibition and altered cell 
growth appear to be events mediated through glucocorticoid 
receptors (GR) since other classes of steroid hormones, 
including aldosterone, estradiol, progesterone, and 
dihydrotestosterone fail to produce these effects. 
Furthermore, direct antagonism of CA 125 in vitro via 
functional blockade of cell surface bound glycoprotein with 
OC 125, anti-CA 125 MAb, produces 70% growth inhibition and 
profound alterations in cell growth pattern. OVCA 433 cells 
growing in OC 125-treated cultures become enlarged, markedly 
polygonal and assume neat, hexagonal arrays. Morphological 
alterations occur in a concentration-dependent manner at 3, 
10, and 30 ug/ml with approximately 25%, 70%, and 100% of 
cells affected, respectively. These results suggest 
decreased cell surface CA 125 expression may mediate 
glucocorticoid-induced growth inhibition and morphological 
alterations, and suggest that the CA 125 determinant plays 
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In 1975, Kohler and Milstein proposed a method for 
fusion of myeloma and murine spleen cells to create 
hybridomas capable of continous production of specific 
antibodies in vitro^. termed monoclonal antibody (MAb). 
Murine monoclonal antibody technology has significantly 
impacted the direction of clinical diagnosis and management 
as well as introduced an unlimited supply of molecular and 
functional probes for study of cellular and molecular 
processes. One outgrowth of this innovation was the 
recognition that tumor cells and cells neoplastically 
transformed via viral or chemical induction, express cell 
surface molecular or macromolecular components which are 
often antigenically distinct from the normal cell surface 
repertoire. A number of murine monoclonal antibodies have 
been prepared against a variety of human neoplasms 
including colorectal, pancreatic, endometrial, ovarian, and 
breast carcinoma as well as melanoma and osteogenic sarcoma. 
The specificity provided by monoclonal antibodies for 
distinguishing neoplastic from normal tissue promises to 
revolutionize cancer diagnosis and therapeutics; monoclonal 
antibodies such as CA 125 have, in many cases, already 
become useful adjuncts to clinical diagnosis and management. 
CA 125, an ovarian carcinoma tumor-associated antigen. 
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is a high molecular weight glycoprotein (Mj-=220,000) 
expressed by 80% of nonmucinous epithelial ovarian carcinoma 
cells.2^3 QQ 125, a murine monoclonal IgGl bearing a 
recognition site for the CA 125 epitope, was raised against 
OVCA 433 cells, a human serous cystadenocarcinoma cell 
line.^ OC125 recognizes a distinct determinant shared by 
malignant ovarian carcinoma cells and fetal coelomic 
epithelium and is not found in detectable amounts in either 
adult or fetal ovary.On this basis, CA 12 5 represents an 
oncofetal protein which may play a role in the complex 
processes regulating cell proliferation and differentiation. 
Ovarian carcinoma is the second most common malignancy 
of the female reproductive system with over 18,500 newly 
diagnosed cases each year.^ The disease often presents 
among women entering the sixth and seventh decades of life 
and, statistically, 1 in 70 females females will be 
affected. Despite new insights and technologic advances in 
the delivery of combined modality therapy, including 
surgery, chemotherapy, and radiotherapy,® the incidence and 
mortality rates of ovarian carcinoma have remained 
relatively constant over the past twenty years at 14 and 9 
per 100,000 per year, respectively. Tragically, the disease 
is often asymptomatic in its early stages and over 2/3 of 
cases are diagnosed when disease is extensive and most 
refractory to treatment. Cytotoxic chemotherapy produces 
regression of residual tumor after cytoreductive surgery; 
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however, surveillance is difficult and even when a complete 
clinical response can be documented pathologically at a 
"second-look" laparotomy, tumor can recur in as many as 28% 
of cases.^ 
CA 12 5 can be detected on ovarian carcinoma cells and 
is elevated in the serum of 80% of ovarian carcinoma 
patients at the time of primary presentation.^A 
radioimmunometric assay developed by Bast et. al. for 
measurement of circulating CA 12 5 has made this tumor 
marker a useful adjunct to diagnosis and surveillance of 
ovarian carcinoma patients. Over 80% of ovarian 
adenocarcinoma patients have circulating CA 125 levels >35 
U/ml at initial diagnosis, while <1% of healthy individuals 
express high levels of CA 125. In one retrospective study, 
elevated CA 125 could be detected as early as one year prior 
to clinical presentation of the disease.While elevated 
levels of CA 125 occurring with a variety of benign 
conditions including menstruation, pregnancy, endometriosis, 
and pelvic inflammatory disease,^preclude widespread 
screening CA 125 levels to promote early detection, the 
serum CA 125 assay greatly aids in clinical decision making 
during therapy. Elevated CA 125 correlates with disease 
course in 80-95% of cases with normalization coinciding with 
disease regression post chemotherapy and rising titers 
coinciding with recurrence confirmed at "second look" 
procedures.The CA 125 marker can also be detected at the 
,r,'•. 1 r ^ a.f -~.ft,, j, : r-^v^rLm y%»V^StyO£i 
-y. ^ V -sd aen «»n«Xi-as‘S IfSOlJitXo 
> .- - . roil ”' ’•V* f ** .40' { 
' *•' 
■ *■ • ".4.'rr^: .;r; !>d .v^’O “*^1 Aj 
‘.-' ■ O'*"? ••> • f J I i. x: sX 
■i-'-'' I ' . 4- - - : ■ Vi i- _ ic •' 
r* 
''-qo.'r-3r V .-, i.'. -I••rar'Piii«*i.oi,fcs*l 
---'■ fJ.‘ '.^ 1 "-1 X’'^»MrS''i4.' 
— ^ J.-. L^ 'it>cu fc* i^3i^i£n 
■ >.'>•- r,|B^*iAva 
• - ■’ - 30ttJ»t.ii 
--V V ■* . ' . .• <• . i . r. ' I •’< i r*, , <'>1\V 
*^ “ ^r.. ..' 4*.A .a :.fav:2s.i txi.lii js-aa^qx# 
.. ' it, f - -.1, ■ . r rC' r', * v’7..? *. 
' .^!z: It r* .t ;?■ '4:'i. j-'i- od 
1.';^ 7.-T •'- trr 4^-. «.'5vv^1 
■ft ■ * rt: : '.; .•••-': i'..-'i 7 i;r:t :r..rlr;-i sncjjAarwW 
< ; • ^ .- 
• V * k ' • jt» • 4 • *_a I T[ Ik*J i. C li* • .*' J V f A-jf 
, Ji;.-•-; t?jv. ; -sjs*•■*»_' . i. i A.i ^a.x > y .,^» 
ir j^r.,.v.' ii.ar.'t. .. rr t-tir* y.i74;„€’7r Cili AO finrjfiji 
- i-trf .<7^; 1 f; sg-jj.,;.,:. ... .3,- , l,^Jg,Ysfli .y'lis70ifj 
rt,: , V- t>''T ' r»<'7 r',*03 4 r 4Vw;“7<*r» * i^K C-O iO J'Cd * 0I> “M 
---7.‘: r. ■ Ifiil i'lnt Vvifc’JeattlVtXI^'rrf'l- iKOU 
M ^ f 7 nco v'xtrf^'rfHONenr il?Xv rnl 
Si^rta iiia-4v;73^«^.c ^?g osXs', «,s:2 dili SO iHiT .•«‘5^.'t‘7K>'jq 
rz ?,c..'- I 
- t-' I 
7 
tumor cell surface in surgical specimens by 
immunohistochemical techniques. Koelma et. al. have found 
marker expression to be a useful adjunct to histology in 
pathological diagnosis.In addition, several groups are 
currently investigating the utility of radionuclide- 
monoclonal antibody conjugates for diagnostic 
immunoscintigraphy and potential use for monoclonal antibody 
guided radioimmunotherapy. 
Although the literature regarding the clinical utility 
of CA 125 continues to expand, the biological significance 
of the glycoprotein bearing the CA 125 epitope remains 
obscure. Recently, Karlan et. al. showed that the CA 12 5 
determinant is highly sensitive to physiologic 
concentrations of glucocorticoids in vitro.They have 
demonstrated that treatment of OVCA 433 cells with lxlO”7M 
dexamethasone results in a >95% inhibition of CA 125 release 
into culture media. Preliminary studies by 
immunofluorescence suggest a concordant decrease in cell 
surface CA 125 glycoprotein expression as well. 
Glucocorticoid-specific inhibition of CA 125 is temporally 
related to previously reported glucocorticoid inhibition of 
OVCA 433 cell growth, inhibition of urokinase and tissue 
plasminogen activator secretion, and profound morphological 
alterations.In addition, Ishiwata et. al. have reported 
that treatment of several human ovarian carcinoma cell lines 
with dibutyryl-cyclic adenosine monophosphate (cAMP) 
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increases CA 125 release. Cyclic AMP has been well- 
characterized as a common second messenger for a variety of 
cell surface hormone and growth factor receptors. Decreased 
CA 125 expression in the presence of hormones having a 
growth inhibitory effect and increased CA 125 expression in 
the presence of a potent growth signal transducer suggests a 
strong relationship between CA 125 expression and regulation 
of cell growth and function. 
This thesis contributes to further definition of the 
hormone sensitive properties of CA 125 expression and its 
functional relationship to cell growth in vitro. In addition 
to examining CA 125 hormonal regulation, I investigated 
whether inhibition of CA 125 might play a role in the growth 
inhibitory effects of glucocorticoids. Studies employing MAb 
directed against the CA 125 epitope as a functional probe 
were initiated to assess specific effects of direct 
antagonism of this glycoprotein. If CA 125 represents an 
oncodevelopmental protein essential to the regulation of 
cell growth, effects on cell growth kinetics, morphology, 
and growth pattern might be expected with CA 125 antagonism 
in vitro by functional blockade of antigen with the anti-CA 
125 Mab, OC 125. 
Specific parameters investigated included: 
1. Characterization of glucocorticoid effects on cell 
surface CA125 expression. 
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2. Characterization of the relationship between morphology 
and CA125 expression in glucocorticoid treated OVCA 433 
cells. 
3. Immunocytochemical localization of the CA125 determinant 
in glucocorticoid-treated and -untreated OVCA 433 cell using 
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technique. 
4. Use of OC125 as a probe to assess effects of CA125 
antagonism on OVCA 433 cell proliferation in vitro. 
5. Characterization of the effect of CA125 antagonism with 
OC125 on OVCA 433 cell morphology and growth patterns. 
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LITERATURE REVIEW 
I. GLUCOCORTICOID-INDUCED GROWTH INHIBITION 
Glucocorticoids Alter Cell Growth 
The a n t i - p r o 1 i f e r a t i V e properties of 
glucocorticoids are well-documented.^0/21,22 Although 
several investigators have reported conflicting results of 
both stimulatory and inhibitory effects of glucocorticoids 
using a variety of cell lines, Durant et. al. point out that 
glucocorticoid effects on growth may greatly vary according 
to the choice of experimental model, the species, and the 
tissue being studied.In addition, Rosner and Cristofalo 
observed differential response between transformed and 
untransformed cells; hydrocortsione consistently stimulated 
the growth of normal fetal lung fibroblasts while virus- 
transformed cells were growth inhibited. Glucocorticoids 
are known to exert specific induction of key enzymes without 
affecting mean protein content; therefore, growth inhibition 
is not likely to represent nonspecific suppression of 
metabolic events. Consequently, glucocorticoid-induced 
effects on neoplastic cell growth offer a valid experimental 
model through which to study cell regulatory processes in 
vitro. 
Primary Events Regulate Cell Growth 
In order to engage in active growth, cells in 
resting phase must traverse a Gq-G^ phase block or 
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restriction point. This cycling between growth arrested and 
proliferative stages is of some consequence since 
populations of cells are obligated both to reproduction and 
to preservation of terminal differentiation events, thus 
requiring individual cells to be highly dependent upon 
internal growth regulatory signals. Pardee et. al. recently 
reviewed the cell biology of normal and aberrant 
proliferation.^^ He reports that the most critical event in 
growth regulatory control occurs 2 hours prior to entry into 
S phase. Cells appear to be committed to initiate DNA 
replication at this restriction point, after release from 
which cells are capable of replication and division even in 
the absence of exogenous growth factors such as PDGF, EGF, 
and prostaglandins required in early G;^* Proliferation is 
thus controlled by events unique to G]^ phase rather than S, 
G2, or M. The latter phases are necessary for the 
completion of cell division amd terminal events (ie. 
cytokinesis) but do not depend upon molecular regulatory 
processes in the same way as Gq and G]^. 
Malignant Cells Exhibit Aberrant Response to Normal Growth 
Regulatory Processes 
Neoplastic transformation may be seen as a defective 
regulaton of cell growth and differentiation induced by 
aberrant regulatin of the biological processes upon which 
cell growth depends. Croy and Pardee have characterized a 
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68,000 dalton protein, p68, produced in large amounts by 
transformed BALB/C-3T3 cells, which is a potential candidate 
for release of normal cells from the putative G]^ phase 
restriction point.^6 These authors theorize that this 
protein is constitutively expressed or stabilized in 
neoplastically transformed cells leading to escape of cells 
from normal growth control. They suggest that transient 
elevation of p68 represents a final commitment to induction 
of cell division requiring a complex sequence of early G]^ 
growth factor regulated events in order to occur. 
Glucocorticoids Induce Growth Arrest in Neoplastic Cells at 
Defined Restriction Points 
Glucocorticoids have been shown to induce a G]^ phase 
block in melanoma cells^^ as well as in several transformed 
cell lines including HeLa cells, NHIK 3025,^^ and DDT]^ MF- 
2.^® The G1 block requires the presence of glucocorticoids 
during the early or late G1 phases. Fanger et. al. have 
suggested a second steroid-dependent restriction point also 
exists in the beginning of S phase which extends the G2/M 
phase of the cell cycle in synchronized HeLa S3 cells. 
These studies show definitively that glucocorticoids can 
regulate progression through the cell cycle; however, 
knowledge regarding the mechanism of steroid-induced growth 
inhibition is presently limited. 
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Glucocorticoids May Regulate Cellular Response to Autocrine 
Growth Factors 
Using the DDT]^ MF-2 cell line, a ductus deferens smooth 
muscle tumor cell line, which is sensitive to growth 
stimulation by androgens via androgen receptors (AR) while 
inhibited by glucocorticoids via glucocorticoid receptors 
(GR),^^ Norris et. al. found that glucocorticoids inhibit 
stimulation of cell proliferation mediated by AR 
enhancement. Inhibition occurs by induction of a Gq/Gj^ block 
18 hours after addition of glucocorticoids.^^ Interestingly, 
addition of exogenous PDGF to cultures overcomes this G]^ 
block independent of androgen receptor level. The authors 
interpreted independence of the glucocorticoid effect from 
AR as evidence for glucocorticoid modulation of autocrine 
rather than genomic events. 
Subsequently, Syms et. al. reported that DDT]^ MF-2 
cells produce c-sis proto-oncogene mRNA, which encodes a 
PDGF-like growth factor which is significantly depressed in 
non-proliferating cells. PDGF is known to induce cell 
transition from resting to G]^ phase rendering them 
competent to respond to other growth factors. 
Glucocorticoids dramatically inhibit c-sis production in 
DDT 3^ MF-2; however PDGF-like product continues to be 
significantly expressed in a glucocorticoid- resistant cell 
line, DDT^ MF-2-GR. Norris et. al. suggested a mechanism for 
glucocorticoid modulation of oncogene expression by 
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demonstration that triamcinolone acetonide treatment of DDT^ 
MF-2 cells prevents release of c-sis poly A+ transcripts 
into the cytoplasm and subsequent production of PDGF-like 
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molecule.This finding strongly supports the theory that 
glucocorticoid effects occur through modulation of cell 
growth factors or growth factor receptor expression. 
Glucocorticoids have been shown to interfere with the 
action of several growth factors but effects vary according 
to primary stimulus. Studies performed on confluent, serum- 
starved 3T3 fibroblasts have shown that glucocorticoids, 
which usually do not affect proliferation under these 
conditions, enhance the stimulatory effect of fibroblast 
growth factor (FGF). In contrast, glucocorticoids 
significantly inhibit stimulation of DNA synthesis by 
exogenous epithelial growth factor (EGF) and prostaglandin 
Baker et. al. found that dexamethasone-induced 
enhancement of EGF stimulation in human foreskin fibroblasts 
parallels an increase in the number of membrane EGF 
receptors.Fanger et. al. have similarly demonstrated 
membrane surface receptor modulation; EGF receptors increase 
following a 24 hour incubation of HeLa S3 cells with 10"^ M 
dexamethasone. ® 
Alternatively, steroids may act through control of 
growth factor synthesis. Glucocorticoids have been shown to 
significantly inhibit cellular release of cytokines 
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including interleukin-1 (IL-1) and colony stimulating 
factor. Furthermore, Besedovsky et. al. have shown that 
when subpyrogenic doses of homogenous human-monocyte derived 
IL-1 or a recombinant form of IL-1 are administered to mice 
and rats, an increase in serum levels of ACTH and endogenous 
glucocorticoids ensues. This effect suggests that 
endogenous glucocorticoids regulate IL-1 release via a 
feedback inhibitory circuit affecting cytokine production 
and activation, providing a physiologic correlation for 
corticosteroid pharmacological suppression of immune and 
inflammatory processes. 
Glucocorticoids have numerous specific effects on 
biological and physiologic processes; therefore, multiple 
autocrine as well as non-autocrine growth regulatory 
interactions are likely to contribute to glucocorticoid 
growth inhibitory effects. Glucocorticoids are known to 
depress glucose uptake and impair ATP formation thereby 
decreasing the cellular energy supply available for 
maintenance of DNA, RNA and protein synthesis. 
Glucocorticoids are also well known to depress synthesis of 
cholesterol and mevalonate derivatives, whereas mitogen- 
induced DNA synthesis and cell proliferation in lymphocytes 
is preceded by a peak of cholesterol synthesis. When 
cholesterol synthesis is directly inhibited by 
hydroxysterols, marked depression of blast transformation 
can be observed. Finally, polyamines, which play an 
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essential role in proliferation as well as development of 
mammalian cells, appear to be under glucocorticoid 
regulation.Depletion of polyamines such as spermidine and 
spermine by inhibitors leads to suppression of cell 
proliferation in both normal and neoplastic cell cultures. 
In S49 mouse lymphoma cells, dexamethasone-induced growth 
inhibition correlated with decreased activity of ornithine 
decarboxylase, a key enzyme responsible for polyamine 
synthesis.Glucocorticoids are also considered to be 
potent inhibitors of prostaglandin synthesis via inhibition 
of phospholipase A2 activity and resultant decreased 
availability of the fatty acid precursor arachidonic 
acid. 
Glucocorticoids exert profound affects on a 
variety of vertebrate tissue during embryonic development. 
These effects include induction of embryonic liver glycogen 
synthesis, maturation of intestine and retinal photoreceptor 
cells, as well as lung cytodifferentiation and accelerated 
synthesis of surfactant by Type II alveolar epithelial 
cells.Often these effects are mediated by glucocorticoid 
induction of enzymes and proteins or augmentation of 
cellular sensitivity to endogenous signals such as enhanced 
pancreatic secretion of insulin in response to glucose. In 
fact, embryonic GR expression occurs relatively early 
during development, even before glucocorticoid-mediated 
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effects, according to Ballard, is an acceleration of 
programmed events, ie. glucocorticoids serve as trigger 
affecting the timing and rate but not the sequence of 
developmental processes. It therefore seems likely that 
glucocorticoids inhibit control of cell proliferation and 
differentiation through targeted events which through 
further investigation may assist in definition of the 
molecular and biological processes governing development. 
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II. TUMOR-ASSOCIATED ANTIGENS 
Many Tumor-Associated Antigens are Carbohydrate Stuctures 
Cells transformed in yitro by yiral or chemical 
tumor promoters or deriyed from tumor extracts haye been 
recognized to express different profiles of cell surface 
structures from their nontransformed progenitor cells which 
are primarily carbohydrate in nature.Monoclonal 
antibodies, directed against these determinants or tumor- 
associated antigens, recognize primarily carbohydrate 
structures on the extracellular domains of cell surface 
glycolipids and glycoproteins. Seyeral groups haye 
characterized monoclonal antibodies which bind determinants 
on the surface of oyarian carcinoma cells. Of 21 
structurally defined epitopes found specifically in 
association with human epithelial oyarian carcinomas, 15 
consist of a glycoprotein determinant, 6 consist of a 
protein determinant, and 2 consist of a determinant 
expressed both on low-molecular-weight glycolipid and 
glycoproteins.^ [Appendix 1] 
In general, carbohydrate changes in glycoproteins 
occur on three orders; a) increases in the number of 
asparagine-linked oligosaccharides resulting in higher 
molecular weight complexes than expressed by untransformed 
cells; b)increases in 0-glycosylated mucin-type structures; 
and c) increases in peripheral side chains in N- or O- 
glycosidic linked structures due to either incomplete 
^■I* . ■> '*L ^-.'VsiLL:iSiSi if?).- ■iQfafiT 
; -’o r.'■!: • r,. t.'iitnolBafii::^ «Xl^ 
,,• W .. ; t VC, " n, ■> tVBV t TJAf, ‘to ♦5-^0610': .7 "fC^Wl/jt 
..->v-. . • ■-*i?;f? ’'i3 ♦-»:- !•• '* f» '*'■♦ i.-,>- • a: «*o»f 
. ,.i >:.hTi<u r};;r ir i;:-.-5.: . 3:U av'5B 
•, . '• -, 1 • v-.. '..' *<-:r.r,r; .V,’iq J»'«H 
'^v.«v - v.jfri'.r <•. r-.i ^c.ri^pe boit3rt’in> , 2»< xbodi^fiB 
, -S. :,.---:‘t .n.TBpX^nr I-DOAeia 
.;. J. • i{=i:-> • - - > ! - . nivXi; tsrt-T HQ 
-.: w ,i P . .(UT' '.*.* ' .3, ' .•';r ' • , v'"''f I J_’ ■ li I ‘4 ifT^Y.Xp 
a:*jt :.!• > ' ii' •<•1, . ■ ■ i>‘T. I jr, L'B.^'. .'.;*3ftrt5> 
^ ^-50- ’-P' r '■•••: 1*341''li- /*dJ f*0 
'..iii:TL'ij -:r P.av.'j vy-I--; I •7l i5»ail4>i' 3^a 
.;• , p-.,•,'.■1 ■ . T,>\7 ' .’ . r n r. 1 ttif rir.c%f rrc I R i rvo;? e 
7i .- •• ’■- r n flQoO VIP ^ 
. :rt IS, ,.:- I -j. iw.f. , tnan: '• i €:'':to^q ^ 
vi - - ,»r'^ tU’*** J B-vr** “C* 
[/ Yi 3'jA ( '’.^^mvJo^.qoo*/ip• 
i;ptfeii'.* s»'tA ALY*K'*J . r.', fll 
C ■ fiJ ftJ. 'Vaj. (tt .JSItiL'IO ^TO 'ItSifOa 
nc L-■ '. Aft-jfeffop f lo i-t-»fl tpft tc<^/s 
;c to.'’.xi'x"‘-p.' rc aad:? ' 
i44tti»:i':h?*Tf,i V 
-o 10 -It :ti .Tivdi iM^mdqisMUi cii z»mt9iQni\o tn* 
j e := -*i>^ f!^ii? -: /^ ’■ ^ r^k^i 
synthesis or neosynthesis^ 
Carbohydrate Synthesis Mav Be Aberrant in Neoplastic Cells 
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Many glycoproteins, such as hormones, mucins, 
immunoglobulins, and blood group determinants, are 
secretory proteins rendered soluble by their carbohydrate 
content which may yary from 2-90% by weight. Most are 
composed of short oligosaccharidic chains joined to a 
polypeptide core by an 0-glycosidic linkage inyolying 
threonine and serine linkages. Alternatiyely, carbohydrate 
may be linked by an N-glycosidic linkage yia an asparagine 
residue, in which case the oligosaccharide moiety is 
assembled on a dolichol carrier before transfer to the 
protein backbone. The protein moiety is assembled on a 
ribosome attached to the rough endoplasmic reticulum (RER) 
before passage through RER cisternae to the Golgi apparatus 
where glycosylation occurs. Monosaccharide units are 
transferred from UDP-sugars to growing polysaccharide 
chains in reactions catalyzed by specific 
glycosyltransferases. The mechanism behind synthesis of 
tumor-associated glycoprotein may inyolye defectiye 
transcription, translation, post-translational modification 
or enzyme specificity, any of which might lead to aberrant 
glycosylation. 
CA 125 is a deteirminant carried on a high- 
molecular-weight glycoprotein (Mj.=220,000) expressed on the 
surface of nonmucinous human oyarian carcinoma cells^® CA 
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125 was initially defined by a murine monoclonal IgG^^ (OC 
125) raised by immunization of BALB/c mice with OVCA 433 
cells, a human serous cystadenocarcinoma cell line.^'^ OC 
125 recognizes distinct molecule expressed by OVCA 433 
cells. During initial screening, its specificity for a 
carcinoma-associated determinant was established by virtue 
of its failure to recognize determinants expressed by 
nonmalignant cells or by an Epstein-Barr virus-transformed 
autologous B cell line established from lymphocytes from the 
donor of the OVCA 433 cell line progenitor. OVCA 433 cells 
growing in vitro express CA 125 on a cell surface 
glycoprotein as well as release significant quantities of an 
antigenically-identical epitope into the culture media. 
Circulating CA 125 can also be isolated from the sera of 
ovarian carcinoma patients and has been shown to be 
immunologically and physically similar to antigen isolated 
from the OVCA 433 cell line. Gel electrophoreisis and 
molecular size exclusion chromatography define the smallest 
molecular subunit expressing the epitope to be >200 
kilodaltons; however, antigen released by OVCA 433 cells or 
isolated from human sera can be associated with a complex up 
to 10® daltons.^® 
The definitive nature of the CA 125 epitope, ie. 
whether the OC 125 binding site recognizes a protein or 
carbohydrate moiety of a high molecular weight 
glycoprotein, remains controversial. Hanisch et. al. 
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originally characterized CA 125 as a carbohydrate structure 
sensitive to periodate oxidation and cleavage by N- 
acetylneuraminic acid."^^ Davis et. al. disputed this result 
based on their studies showing relative stability of CA 125 
subjected to periodic acid treatment, and suggested that 
Hanisch's contradictory results were obtained under 
conditions which destroyed the integrity of CA 125 by virtue 
of its heat sensitivity. This group further established 
complete loss of CA 125 activity after protease digestion 
and urea treatment and demonstrated retention of activity 
despite exhaustive treatment with exoglycosidases.These 
findings led Davis et. al. to conclude that CA 125 
represents a conformationally-dependent epitope with 
recognition of a protein perhaps in association with 
carbohydrate dependent upon preservation of the integrity of 
secondary and tertiary structure. Recently, Leoni et. al. 
reported two monoclonal antibodies, CAM0v2 and CAMOvS, 
raised against ovarian carcinoma cyst fluid glycoproteins, 
which can detect saccharidic chains expressed on the same 
molecule and occasionally coexpressed with CA 125.^® These 
authors are in agreements with Davis' hypothesis of a 
conformational epitope suggesting that two saccharidic side 
chains, recognized by CAM0v2-CAMOvS and a protein backbone 
contribute to the structure complementary to the OC 12 5 
site. 
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Iinmunopathological Correlations of CA 125 Expression 
Current definitions of cancer stress that 
processes leading to neoplastic transformation may reflect 
blocks or aberrations in the regulatory processes controling 
normal growth and differentiation.In support of this 
theory, Hakamori points out that most tumor-associated 
antigens are defined by monoclonal antibodies recognizing 
normal cell surface molecules, usually absent or present in 
insignificant quantities, which have been augmented or 
modified by neoplastic transformation in a way which 
renders them more antigenic.For example, several TAA's 
appear to represent derivatives of blood group antigens 
noirmally not expressed in an individual, ie. A-like antigen 
may be present in colonic cancers in hosts of O or B type. 
Often, determinants are not restricted to neoplastic 
expression, as certain antigens may be detected in a tissue- 
specific manner or at specific points during normal 
embryonic development, earning their classification as 
oncofetal proteins. 
CA 125 represents one such glycoprotein demonstrating 
oncofetal expression. CA 125 is present in normal adult 
tissue derived from coelomic epithelium and nonmucinous 
common epithelial ovarian tumors; however it cannot be 
detected in normal fetal or adult ovary.^ This conforms with 
the common belief that the majority of ovarian tumors are 
felt to arise from the germinal epithelium of coelomic 
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origin which covers the ovarian surface and lines 
subcapsular cysts. Immunohistochemical localization of 
fetal CA 125 detects antigen expression in embryonic pleura, 
pericardium, peritoneum, mullerian duct, and amnion,^ as 
well as in normal adult tracheobronchial lining.cA 125 is 
also present in a variety of human secretions including 
human milk,^® cervical mucus, and seminal fluid.In 
terms of its neoplastic expression, Kabawat has demonstrated 
CA 125 in 82% of serous cystadenocarcinomas and 100% of 
benign and borderline ovarian tumors. A variety of 
nonovarian malignancies express CA 125 as well including 
adenocarcinomas of the pancreas,^® endometrium, fallopian 
tube, and endocervix^"^ as well as a small minority of lung, 
breast, colorectal carcinomas and melanomas.^ 
Feizi has suggested carbohydrate structures 
associated with neoplastic and transformed cells represent 
developmental and growth regulatory proteins.He invokes 
as proof the existence of highly-conserved oligosaccharidic 
structures such as the fucosylated N-acetylactosamine bound 
by Mab anti-SSEA-1, an epitope expressed by the 8-cell-stage 
mouse embryo and shared with gastrointestinal glycoproteins, 
human ovarian cyst proteins, human adenocarcinoma 
glycolipids, and human milk oligosaccharides. In addition, 
if one takes note that one of the first reports of a tumor- 
associated antigen demonstrated that the anti-melanoma 
monoclonal antibody which defined the TAA significantly 
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suppressed human melanoma tumor growth in athymic mice,^^ 
the concept of tumor-associated antigen expression as a 
requirement for neoplastic growth is a highly provocative 
one. 
The observation that activated oncogenes including 
erbB. fms. neu. sis. and ras encode products expressed as 
trans-membrane glycoproteins with large extracellular 
domains 57,58,59 lends further support to this hypothesis. 
Recently, Drebin et. al. demonstrated MAb anti-pl85, when 
used to antagonize neu-oncoqene encoded product, pl85, 
expressed in high levels by neuroblastomas and various 
adenocarcinomas, significantly inhibits anchorage 
independent growth of neu-transformed NIH 3T3 cells^® as 
well as tumorigenic growth of transformed cells implanted 
into nude mice.^^ 
The characterization of another growth-related 
melanoma-associated antigen, p97, recognized by MAb 9.2.27, 
represents one of the most detailed physical and functional 
analyses to date of a glycoprotein implicated in growth 
regulation. Melanoma-associated p97 is a sialylated 
transmembrane carbohydrate glycoprotein (Mj-=250,000) 
expressed by melanoma, nevi, and fetal intestine.In a 
study which precedented the use of monoclonal antibodies as 
functional probes for growth and differentiation effects. 
Harper and Reisfeld demonstrated that anti-p97 MAb inhibits 
anchorage-independent human melanoma cell growth and blocked 
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cell spreading and adhesion to substratum.1986, Rose 
et. al. purified, cloned, and sequenced p97 mRNA in order to 
determine its amino acid sequence and core carbohydrate 
structure.Interestingly, the epitope recognized by Mab 
9.2.27 exhibited 39% homology to human serum transferrin in 
the region of the iron-binding pocket. Although the growth 
regulatory properties of transferrin have been well- 
established, no experimental proof exists demonstrating p97 
uptake of transferrin-bound iron; therefore, a growth 
regulatory role for p97 remains speculative until such 
functional studies can be performed. 
A new approach to the characterization of 
oncofetal antigens which has recently appeared in the 
literature is the direct analysis of proliferation- 
associated determinants. Devendra et. al. raised MAb anti- 
Proliferation Associated Antigen (anti-PAA) by immunization 
of mice against activated human T-cells in mixed-lymphocyte 
cultures(MLC).These authors found a 2-6 fold increase 
over resting T cells of PAA expressed by MLC- and 
phytohemagglutinin-stimulated T cells. Transformed 
hematopoeitic cell lines exhibited dramatic increases in PAA 
with an acute lymphocytic leukemia T cell line and an EBV- 
transformed B cell line showing 15- and 16-fold increased 
anti-PAA binding, respectively. Anti-PAA demonstrated an 
oncofetal pattern of staining with significant quantities of 
antigen expressed by chorionic villi, trophoblasts, actively 
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proliferating normal adult skin, and colonic epithelia, as 
well as benign hyperplastic tissue. As more and more 
investigators undertake projects aiming toward structural 
and functional definition of tumor-associated antigens, 
their biological relevance ought to lead to new concepts of 
how extracellular and membrane structures contribute to the 
appearance of neoplastic clones and tumorigenic growth. 
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MATERIALS AND METHODS 
CELL LINES OVCA 433 human ovarian carcinoma cells, derived 
from a human serous cystadenocarcinoma of the ovary as 
described previously,^,67 ^/ere grown at 37°C, 5% CO2 in 
Minimal Essential Media (MEM)(Gibco, Grand Island, NY) 
supplemented with 10% fetal calf serum (ECS), ImM sodium 
pyruvate, 2mM L-glutamine, and 100 U/ml 
penicillin/streptomycin (Gibco). SK-OV-3 and Caov-3 cell 
lines, derived from human ovarian adenocarcinomas, were 
grown in McCoy's MSA and Dulbecco's Modified Eagle's Media 
(Gibco), respectively, with 10% PCS, 2 mM L-glutamine, and 
100 U/ml penicillin/ streptomycin added. 
BIOLOGICALS Dexamethasone (Steraloids, Wilton, NH) was 
prepared freshly in deionized water at 1 X 10“^M, 
sterilized through Millex-GS 0.22 urn filters (Millipore, 
Bedford, MA) and diluted appropriately before addition at 
1:2 to 1:10 to final concentration of 10“^M-10-^*^M 
^examethasone, cortisol, aldosterone, estradiol, 
dihydrotestosterone, and progesterone used in the 
specificity experiments was freshly prepared in culture 
media from stocks stored in 100% ethanol at -20°C. 
OC 125 MAb, purified from mouse ascites, kindly 
supplied by Dr. Vincent R. Zurawski, Jr.(Centocor, Malvern, 
PA) was diluted in fresh media from stocks stored at -80°C 
in Tris:EDTA buffer. Before addition to cell culture, OC 
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125 was filter sterilized through Millex-GV low protein 
binding 0.22uin millipore filters (Millex, Bedford, MA). 
Whole mouse IgG and mouse IgG^ fragment (Jackson 
Imuunoresearch, West Grove, PA) and mouse IgG]^ Kappa from 
MOPC 21 ascites (Sigma, St. Louis, MO) were similarly 
prepared. 
IMMUNOCYTOCHEMISTRY An indirect ABC immunoperoxidase 
technique based on a method previously described by Childs 
et. al.^® was employed. Briefly, OVCA 433 cells were 
harvested with 0.25% trypsin and replated in dual-chambered 
Lab-Tek Tissue Culture Chamber/Slides (Miles Scientific, 
Naperville, IL) at a seeding density of 8.5x10"^ 
cells/chamber. After 4 days, confluent monolayers were 
washed with O.OIM Na Phosphate, .015M NaCl pH=7.4 (PBS) and 
fixed overnight at 4‘^C in 4% EM-grade paraformaldehyde 
(Electron Microscopy Sciences, Fort Washington, PA) in PBS. 
Fixed monolayers were washed and incubated with 6% normal 
goat serum to block nonspecific staining. Primary antibody, 
MAb OC 125, was applied at to monolayers at 1-40 ug/ml 
overnight at 4°C. Cells were rewashed with PBS before 
application of biotinylated anti-mouse IgG (Vectastain ABC 
kit: Vector Laboratories, Burlingame, CA), 0.1% 
crystalline-grade bovine serum albumin (BSA) (Sigma, St. 
Louis, MO) in PBS for 3 0 minutes at RT. After several 
washes in PBS, horseradish peroxidase avidin-conjugate, 
prepared 15-30 minutes in advance, was applied to 
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monolayers for 30 minutes. Cells were again washed and a 
substrate prepared in the following manner applied for 7-10 
minutes or until a blue-black pigment no longer continued to 
form. To prepare substrate, 6 mg diaminobenzidine and 0.33 
g nickel ammonium sulfate (Sigma, St. Louis, MO) were added 
to 30 ml of .05M Sodium Acetate buffer, pH=6.0, sonicated, 
filtered and 90 ul 30% H2O2 added immediately before use. 
The substrate reaction was quenched in tap water and 
coverslips applied over 15% glycerol. 
PHOTOGRAPHY Photos demonstrating glucocorticoid- and OC 
125-induced morphological alterations were taken under a 
Zeiss phase contrast microscope with lOX, 20X, and 40X 
objectives through a green interference filter. Photographs 
demonstating immunocytochemical localization of CA 125 were 
obtained with the aid of a Sony Differential Interference 
Computerized Videoplan image processor. 
MICROCULTURE CELL GROWTH ASSAY Growth inhibitory effects of 
CA 125 and dexamethasone were assessed using a methylene 
blue uptake previously described by Finlay et. al.^^ OVCA 
433 cells were harvested with 0.25% trypsin and replated at 
2000 cells/well in 96-well flat bottomed-plates with varying 
concentrations of OC 125 or dexamethasone. Days 1-7 post 
seeding, culture media was removed and 200 ul of 0.5% 
methylene blue/50% ethanol was added to each well for 3 0 
minutes. After solubilization of cells in N-lauroyl- 
sarcosine, plates were subsequently washed in deionized 
ba,-;*. r.v .wojun.l.® Ot i^^.!(iy_&toncm v'" 
~xol r-«i: ;.a»4;^ sq' » 
<■• ■-M.?,-),/c.vin •t!rr©'j«v i'Xr^nid- -^cXoi jLf:S‘fiu to at>4'.unii!j 
.i.?!b;.r, rvPiW rti''. „ rnurpj-iSixi-Towuf, ’p'‘"■'' 
.' •''b• . !■ fi' ■- ■ ■ w*._ '•♦n.', la lii '0€tt(f ■ 
- -ji '*', r ‘ i t-^febbfi. -OjtW ','■ bn?^ barr©:fii’j 
; t« » .“ - 1 ■•iijj- bfiiA r.'C' t .J ^ !r,iiw'4 ki'lJ'ftiSX*© 
3 -c- :• \» I p #• .V : . i v'O I.M ! ■ •> ^ ■'■ I *'»'J? -• V »;>cr 
i b,-rf. .. I- '1^ j ■'.'j^*'",,' •... ^;.v- „ .t **3: ~iu nr:*o^'orH 
» ~ ,r, .TTr r,» .» -w 
a » -^ '. • , J t < - ^ C. i Ji?-' ■■' ' ■ v“i ■ - br i r 
■ V ; .},» '•■ J :•', 4 u ;•.■:X 0*11 ts:. ..* .•; Cl nstistiq dXslssS 
>i,^,'r ,»■■■:•/:^':>>\'2 .'-.a -i’-§ •/£ ^4* . 
■ V--4* ' ;ta <•» .. t' .V! ; aiij rr*ti'iO.r •/■•-'-irit/tce.i pitf T*54’<n.'-C?«f>b 
»-;3, >.';'<'•>:••-’M C ror' r. tC bi f. -.f,, ■! I frv*«iJk3i 
f: 
’i'- .,..-'-'jq tp»ai rf«Xcf04!biV b»si'7^ 
■’•■1 ’•'10'Hf. V. I r "Vr.-,*^ .Ti'VrWSSJ .l.*'r.. 
s>. >rs *:c'‘.3**''-* .-J' ^-s J ari-'err, AO 
■■i' '■>■ • '■’' !'■A J.,* ,i •',!■■ X'-’ ' »-!J.5''3*->lk Vii-tq fa'!#.'■?»jt/. 
.?' •*•■■“,:. 1 r':.'JL tr:^, '<*V -j 1'Mv t'O-.-'a :r ^rr nrf sfinv) C't»* 
/■ 
i;- .'• ■ "..'k X*1*. >r; J :fc~'J SttLJ ' *;■ -■ »V3 II.>V*YaIid&S OOiJ'S 
Tsaij '-,1 -'Yeiu .,':ii.To.iKO.r,f1^air>45 ''q dCi XiO -♦tti 
*d.ij i '< .*•"? t>rT« fct>i>VO<frsr-t f ♦*ar**i*i ux> -3 
ji ’3:rj (iiDfStf :’4 ««&'««# lotWiitr fQ-C\*'*jr'f 
- f "to . S rteitliW , 'i 
fo3».-icox*£i n4 
30 
water baths until rinsewater cleared . Methylene blue uptake 
in fixed monolayers was correlated with absorbance at 600 nm 
determined on a Titertek Multiskan Plus ELISA (enzyme- 
linked immunosorbent assay) plate reader. 
CONDITIONED MEDIA Conditioned media enriched with CA 125 
was obtained by growing OVCA 433 cells to confluence 3-4 
days, changing the media, and then permitting CA 125 to 
accumulate over a 7 day period before harvesting. 
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RESULTS 
Dexamethasone-induced iriorpholoaical alterations 
OVCA 433 ovarian carcinoma cells were harvested with 
trypsin and replated with fresh media or IxlO-^M 
dexamethasone and permitted to grow to confluence. After 4 
days in culture, dexamethasone-treated cells exhibited 
significantly altered morphology as compared to controls; 
cells became enlarged, flattened, and rounded with 
disappearace of cell processes as compared to controls. 
(FIG. 1) There was significant variation in dexamethasone- 
sensitivity among a cell population as within a cell 
monolayer multiple clusters of cells with altered morphology 
could be observed while many cells remained unaffected. The 
earliest observable effect was the appearance of large, 
multinucleated cells 48 hours after plating. (FIG. 1) 
Immunocvtochemical detection of CA 125 
To assess the effect of dexamethasone on OVCA 43 3 CA 
125 expression, OC 125-binding sites were determinied using 
an indirect immunoperoxidase technique. OVCA 433 
minicultures were seeded with 8.5XIO4 cells and fresh media 
or media containing 1 X 10“^M dexamethasone and grown to 
confluence (4d) before fixation and staining with OC 125. In 
this technique, a secondary antibody-peroxidase conjugate, 
anti-mouse IgG, when complexed to cell surface bound CA 125 
undergoes a substate reaction depositing a characteristic 
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blue-black pigment in situ. Dexamethasone-treated OVCA 433 
cell monolayers consistently stained less intensely than 
untreated controls. When concentrations ranging from 10“5m 
to 10“^M dexamethasone were tested, this effect occurred in 
a dose dependent manner with maximal CA 125 inhibition 
observed at 10”^M and 10“^M dexamethasone. To compare the 
effect of different classes of steroid hormones on 
inhibition of CA 125 expression, OVCA 433 human carcinoma 
cells were treated with lxlO”^M concentrations of estradiol, 
dihydrotestosterone, progesterone, aldosterone, cortisol, 
dexamethasone or no steroid at all. CA 125 inhibition was 
found to be specific to the physiologic and synthetic 
glucocorticoids, cortisol and dexamethasone, while other 
classes of steroids yeilded no effect. 
As observed with dexamethasone-induced morphological 
alterations, there was marked heterogeneity of staining 
intensity among individual cells or islands of cells within 
glucocorticoid-treated monolayers. In general, smaller 
cells and those with cytoplasmic extensions growing in a 
vermiform pattern present in dexamethasone-treated and- 
untreated monolayers stained most intensely. These cells 
exhibited cell surface and diffuse granular cytoplasmic 
staining; whereas the enlarged, flattened, polygonal cells 
more characteristic of the cortisol- and dexamethasone- 
treated monolayers demonstrated attenuated or a faint blush 
of staining often in a perinuclear distribution.(FIG. 2) No 
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correlation was observed between the presence of multiple 
nuclei and staining intensity. Cell monolayers in which the 
primary antibody incubation step with OC 125 was ommitted 
demonstrated only minimal background staining. 
In order to define whether a quantitative relationship 
exists between stereotypic dexamethasone-induced morphology 
and CA 125 expression, I attempted to analyze immuno- 
peroxidase-stained steroid-treated and -untreated OVCA 433 
cells using an image processor with gross morphometric and 
gray scale analysis capabilities. Unfortunately, this line 
of investigation could not be pursued secondary to poor 
contrast and inaccessibility of equipment with potential for 
morphometric analysis of microscopic specimens. 
Immunolocalization of CA 125 Determinant 
To further delineate differences in the pattern of 
staining induced by dexamethasone, immunoperoxidase- 
stained, fixed monolayers of OVCA 433 cells were observed 
with the aid of a video-enhanced image processor and 
differential-interference screen to permit localization of 
intracellular CA 125. The majority of cells in the control 
population exhibited dense immunoprecipitate at the cell 
surface. (FIG. 3) Cells treated with 10”^M dexamethasone, in 
contrast, frequently exhibited decreased cell surface 
staining relative to controls and a dense, granular sphere 
of immunoprecipitate restricted to the perinuclear area. 
(FIG. 4) The population of cells displaying this pattern of 
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staining was entirely consistent with the glucocorticoid- 
sensitive subpopulation displaying increased cytoplasmic 
volume and polygonal growth. At this level of resolution, 
staining could not be definitively localized to the 
perinuclear cytoplasm or the nuclear membrane. 
Dexamethasone effect on cell growth 
To determine the effect of glucocorticoids on cell 
growth rate, OVCA 433 ovarian carcinoma cells, grown in 96- 
well plates in the presence of varying concentrations of 
dexamethasone were assayed using the , microculture cell 
growth assay. Dexamethasone inhibited growth up to 32% over 
controls occurred in a dose-dependent manner with maximal 
inhibition occurring at 10-^M and 10“^M dexamethasone.(FIG. 
5, FIG. 6) Growth inhibition was most noticeable day 4 and 5 
post seeding although treated and untreated cultures 
ultimately grew to similar density by day 7. 
Antagonism of CA 125 determinant 
Because the results above suggest that GR mediated 
alteration of cell morphology is associated with decreased 
expression of CA 125, I examined this relationship further 
by direct antagonism of CA 125 determinant via induction of 
a functional blockade with OC 125, anti-CA 125 MAb. 
Interestingly, MAb antibody OC 125, added to freshly plated 
OVCA 433 cells in vitro, induced profound alterations in 
morphology and growth pattern at 4-5 days. Cells became 
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markedly enlarged and polygonal with centralization of 
nuclei, cytoplasmic thinning, and decreased 
granularity.(FIG. 7) These changes occurred in a dose 
dependent manner at 3, 10, and 3 0 ug/ml with approximately 
25%, 70%, and 100% of cells affected, respectively. In 
contrast to normal OVCA 433 growth which is primarily 
disordered and dependent upon contact-inhibition, OC 125- 
treated cells assumed a neat, hexagonal array with few cells 
overlapping. While untreated cultures reached confluence at 
4-5 days, OC 125-treated cultures were considerably less 
dense and just beginning to extend cytoplasmic bridges 
between islands of cells at 4 days, characteristic of 
preconfluent growth. Within 24-48 hours of the appearance of 
peak morphological alterations, OC 125-treated cells 
consistently lifted off the plastic in sheets of cells while 
control OVCA 433 cells remained firmly adherent throughout 
the growth period. Cell detachment in wells plated with 10 
ug/ml OC 125 occurred >24 hours earlier than detachment in 
wells with 30 ug/ml OC 125. 
Specificity of the OC 125 effect 
In order to demonstrate that recognition of CA 12 5 
determinant as opposed to nonspecific effects of 
immunoglobulin or mouse ascites is a requirement for growth 
effects, OVCA 433 cells were incubated with 10 ug/ml whole 
mouse IgG, mouse IgG fragment, or a nonspecific 
monoclonal immunoglobulin raised in MOPC 21 mouse ascites. 
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None of these antibody preparations altered morphology or 
growth pattern.(FIG 8) Similarly, cells incubated with MAb 
directed against irrelevant epitopes [ie. anti-tissue 
plasminogen activator and anti-HCG (beta subunit] were 
morphologically identical to control OVCA 433 cells at 
confluence.(FIG. 9) OC 125 at 10 ug/ml also failed to affect 
morphology, growth pattern, and adherence properties of 
Caov-3 and SK-OV-3 cell lines, two ovarian carcinoma cell 
lines previously shown to express no or insignificant 
quantities of CA 125.^® (FIG. 10). 
Finally, to confirm that the OC 125 growth effect is 
mediated via specific recognition of cell-bound determinant 
and not by antagonism of free CA 125 activity, OVCA 433 
conditioned media known to contain high quantities of CA 125 
was added to freshly plated cell cultures containing 30 
ug/ml OC 125 plating. CA 125-enriched conditioned media 
failed to inhibit the OC 125 effect on cell growth and 
growth pattern, nor was inhibition of dexamethasone effects 
observed at 10“^M steroid. 
Determination of OC 125 effect on cell growth 
When increasing concentrations of OC 125 were added to 
OVCA 433 cells ij\ vitro. a dose-dependendent growth 
inhibitory effect of 72% at 30 ug/ml and 26% at 10 ug/ml 
was noted. (FIG. 11, 12) Growth inhibition was observed as 
early as 48 hours post seeding of cultures. Freshly seeded 
OVCA 433 cell cultures display rapid exponential growth 
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which declined with time in culture as cells approached 
confluence. Interestingly, this growth rate decline was 
accelerated in cultures containing 10 and 30 ug/ml OC 125 
(FIG. 11) and cells entered stationary phase at 6-7 days as 
did controls despite markedly decreased culture density. 
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DISCUSSION 
Ovarian carcinoma cells, OVCA 433, grown in culture 
media containing lxlO“^M dexamethasone demonstrate 30% 
growth inhibition and significant morphological 
alterations. In agreement with previous findings,a 
subpopulation of dexamethasone-sensitive cells become 
enlarged, loosely packed, flattened, and more polygonal. 
Using an immunoperoxidase technique, this work demonstrates 
that the dexamethasone-sensitive subpopulation of OVCA 433 
cells is identical to a subpopulation of cells exhibiting 
significant inhibition of CA 125 cell surface expression in 
the presence of 10“^M dexamethasone. This modulation of cell 
surface CA 125 appears to be mediated by steroid-specific 
GR, previously demonstrated in these cells,since CA 125 
inhibition was observed only for OVCA 433 cells treated 
with dexamethasone or cortisol. Treatment with other 
steroids, including estradiol, dihydrotestosterone, 
aldosterone, and progesterone in equivalent concentrations 
failed to produce altered morphology or antigen expression 
in these cells. In addition, peak inhibition of CA 125 was 
observed at glucocorticoid concentrations corresponding with 
those necessary to produce maximal growth inhibition in the 
microculture growth assay, suggesting CA 125 expression and 
growth inhibition of intimately related processes. 
In order to determine whether decreased cell surface 
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expression of CA 125 mediated by GR is the primary event 
leading to induction of growth inhibition, a functional 
blockade of CA 12 5 determinant was accomplished by 
incubating freshly plated OVCA 433 cells with varying 
concentrations of OC 125, anti-CA 125 MAb. OVCA 433 cell 
monolayers treated in this manner exhibited dramatic changes 
in morphology and cell growth at 3, 10, and 30 ug/ml OC 125 
with 25%, 70% and 100% of the cells affected, respectively. 
Cells became significantly enlarged, flattened, and 
polygonal with decreased granularity and an increased 
cytoplasmic:nuclear ratio. Monolayers demonstrated complete 
loss of the "garlands and whorls" pattern of growth 
described by loachim et. al.^^ characteristic of ovarian 
cystadenocarcinoma cell lines; rather they assumed a 
nonoverlapping, hexagonal array and, in some areas, cells 
adjacent to bare plastic resembled the epithelial lining 
found in microcysts of human serous cystadenocarcinoma. 
(FIG. 13). 
In addition, OC 125 significantly inhibits OVCA 433 
cell growth by 3 0% and 70% at concentrations of 10 and 3 0 
ug/ml, respectively. At these concentrations, OC 125 
induces OVCA 433, which grow firmly adherent to plastic, to 
lift off the culture dish in sheets of cells as they 
approach stationary phase. OC 125 interference with some 
mechanism of cellular adherence to substratum is likely 
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the microculture growth assay (FIG. 10, 11) reflecting the 
failure of cells in these wells to remain attached to 
plastic during fixation in ethanol. Adequate fixation 
depends upon the availability of matrix proteins which 
normally contribute to cell adhesion, and therefore, these 
observations may be consistent with an OC 125-induced 
modulation of proteoglycans synthesis or secretion. 
Paradoxically, disassociation from the culture dish appeared 
earlier in cultures plated at 10 ug/ml than at 30 ug/ml. One 
explanation for this finding may be that the presence of OC 
125 in vitro is a biological stressor inducing increased 
utilization of nutrients and growth factors available in the 
media, resulting in the arrest of nonessential metabolic 
activity. The increased metabolic state concomitant with 
active cell proliferation may also be considered as a 
biological stressor and may compound the OC 125 effect 
accelerating consumption of cell nutrients. This would 
explain why cell detachment occurs precociously in more 
actively proliferating OVCA 433 cultures containing 10 
ug/ml OC 125 while severely growth inhibited cultures with 
30 ug/ml are relatively protected. Accelerated nutrient 
consumption may also explain why OC 125-treated OVCA 4 33 
cells enter stationary phase at decreased cell density 
relative to controls; however, the onset of stationary phase 
primarily may be a function of time in culture and the half- 
lives of competence factors rather than cell density. It is 
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also interesting to note that many cell matrix proteins such 
as fibronectin are also considered to be competence 
factors,and, therefore, cell proliferation and two- 
dimensional configuration may be dependent on factors 
mediating cell adhesion. 
In order to establish whether growth inhibition and 
altered morphology occur through specific interaction of 
MAb with the CA 125 determinant, OVCA 43 3 and two 
additional human ovarian carcinoma cell lines which do not 
express CA 125 were grown to confluence in the presence of 
OC 125. The cell enlargement and polygonal growth which was 
observed in OVCA 433 cells failed to occur in either Caov-3 
or SK-OV-3 cells after a 4 day incubation period with OC 
125. Littlefield previously documented that CA 125 is found 
in high quantities (>1000 U/ml) in the media of 7 day OVCA 
433 cultures but is not dectable in either Caov-3 or SK-OV-3 
cultures. In addition, OVCA 433 cells were grown in the 
presence of affinity-purified whole mouse IgG and mouse IgG 
fragment, as well as several monoclonal immunoglobulins 
recognizing irrelevent epitopes, none of which produced 
stereotypic effects. These findings confirm that 
morphological and growth effects noted are specific to 
recognition of the CA 12 5 determinant. Failure of free CA 
125 found in high quantities in OVCA 43 3 7d conditioned 
media to inhibit the OC 125 effect strongly suggests that a 
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a requirement for altered growth pattern since this effect 
cannot be overcome by effectively adding back CA 125 product 
to culture media. 
These experiments suggest that active cell 
proliferation is in part dependent upon the availability of 
of a high-molecular weight glycoprotein bearing the CA 125 
epitope on the cell surface membrane. Decreased cell surface 
availability of CA 125 mediated by glucocorticoids or 
functional blockade with OC 125 MAb is associated with 
growth inhibition and morphological alterations. Although 
the relationship between growth patterns observed with 
glucocorticoids and OC 12 5 is uncertain, they bear several 
similarities (ie. increased cytoplasmic volume and polygonal 
growth) which suggest that common biological events may 
mediate both. It is interesting to note that OVCA 433 cells 
harvested with trypsin from monolayers grown to confluence 
in the presence of OC 125 and replated into culture flasks 
containing fresh media exhibit poor plating efficiency with 
only a minority of cells adhering to plastic in colonies <40 
cells at 4 days. That these colonies demonstrate active, 
albeit significantly depressed growth, suggests that 
decreased CA 125 expression represents a partially 
reversible commitment step necessary for cells to traverse 
the cell cycle or to enter into terminal differentiation. 
Alternatively, adherent cells growing in fresh media may 
represent an OC 125-resistant subpopulation of cells which 
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have to some extent escaped the inhibitory effects of Mab. 
This work demonstrates significantly decreased cell 
surface expression of CA 125 determinant in cells treated 
with 10“^M dexamethasone as compared to controls. Hakamori 
and Kannagi^^ have theorized that cell surface antigen 
recognition is highly sensitive to antigen concentration and 
crypticity, where crypticity refers to modification of 
antigen secondary or tertiary structure or the configuration 
of the glycoprotein in the membrane lipid bilayer. It is 
unlikely that the inhibition of antigenicity induced by 
glucocorticoids, well known to affect cholesterol synthesis 
and membrane fluidity, represents a dilution of cell surface 
antigen via migration since cell surface glycoproteins are 
relatively immobile structures regulated by regional 
cytoskeletal elements and substratum. Modification of the CA 
125 determinant rendering it functionally obsolete via 
enzymatic processing is possible and its structural 
derivative could not be distinguished by immunoperoxidase 
staining. 
Little is known regarding mechanisms behind the 
regulation of cell surface CA 125 expression, although the 
appearance of altered intracellular distribution of CA 125 
in glucocorticoid-treated OVCA 433 cells may shed light on 
how cell surface antigen modulation occurs in actively 
proliferating cells. Immunoperoxidase-stained OVCA 433 cells 
at confluence exhibit a dense precipitate at the cell 
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surface, reflecting CA 125 membrane expression; staining in 
dexamethasone and cortisol-treated OVCA 433 cell monolayers 
at confluence appears to be primarily restricted to a 
perinuclear granular deposit. This perinuclear distribution 
of CA 125 may represent neosynthesis or neoglycosylation 
occuring in response to loss or modification of cell surface 
CA 125 or as a direct effect of glucocorticoids. Although 
carbohydrate hormone receptors have been documented in the 
nuclear membrane,the spherical configuration and 
granularity of stain rules against nuclear membrane 
staining. This distribution, however, is consistent with the 
rough endoplasmic reticulum and Golgi apparatus where 
glycoprotein synthesis and glycosylation is known to take 
place.'76,77 
Rosen et. al. have suggested that the most likely 
precursor storage site for carbohydrate receptors is the 
Golgi apparatus and that glycosylation serves as the rate 
limiting step for receptor synthesis.^® Receptor expression 
is accomplished by integration of Golgi vessicles containing 
glycosylated integral membrane proteins into the cell 
surface. Membrane turnover via shuttling of Golgi vessicles 
has been induced as another mechanism governing regulation 
of hormone receptors.In fact, Palade has proposed a 
protective role for Golgi vessicles; he postulated that the 
Golgi apparatus serves as an intermediate in a cycling 
mechanism where receptor is internalized to escape 
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degradation (ie. lysosomal) and subsequently reincorporated 
into the surface membrane.®® Increased perinuclear CA 125 in 
parallel with decreased cell surface expression may 
similarly reflect receptor internalization and storage 
within the Golgi vessicles as opposed to antigen loss 
followed by neosynthesis. Delineation of a primary 
mechanism, however, will require further investigation via 
classical pulse-chase S-methionine labeling in combination 
with electron microscopy. 
These studies suggest that modulation of cell surface 
CA 125 expression is a process which may serve an integral 
function for control of cell proliferation and cell:cell 
interactions in ovarian carcinoma. One caveat presented by 
these results, however, is the heterogeneity observed for 
expression of CA 125 as well as for sensitivity to 
dexamethasone among OVCA 433 cells. Heterogeneous 
immunoperoxidase staining is also highly characteristic of 
primary human serous ovarian adenocarcinomas which display 
intimately mixed positive and negative cells when stained 
for CA 125.®'^ Heterogeneous expression is not unique to the 
CA 125 marker. A host of tumor-associated antigens are 
variably expressed within primary and metastatic tumor 
specimens as well as within tumor cell lines. 
Several theories have been invoked to explain antigen 
modulation including antigen shedding and accelerated 
frequency of mutational events. If one assumes that a tumor- 
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associated antigen is an aberrantly processed glycoprotein 
conserved because its expression conveys a selective 
advantage, one must also consider that variable expression 
may arise because an antigen plays a function which is not 
critical to preservation of neoplastic growth. This 
statement does not appear to hold true for CA 12 5, since 
100% of cells can be induced to enter a growth-inhibited or 
arrested phase and undergo morphologic alterations in the 
presence of high doses of OC 125 despite variable antigen 
expression. Therefore, while excessive expression of an 
oncodevelopmental antigen, such as CA 125, normally 
suppressed in terminally differentiated tissue, is one 
possible mechanism leading to uncontrolled proliferation, 
antigen heterogeneity suggests that, although they may be 
clonally-derived, as tumors progress they become mosaics of 
subclones with various cell regulatory escape mechanisms. 
The biological processes leading to transformation are as 
complex as the vast number of molecular interactions which 
must take place for normal growth regulation to occur; 
functional definition of tumor antigens, however, will 
likely shed light on how tumorigenic cells escape 
constitutive growth regulation. In addition, perhaps 
definition of TAA function will inspire innovative 
approaches to pharmacological inhibition and permit more 
prudent selection of antigens for use as prognostic markers 
or targets for radionuclide-antibody conjugates. 
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FIG. 1. Effect of dexamethasono treatment on OVCA 433 cel] 
morphology. Freshly plated cell were grown in (a) MF.M, 10% 
FCS or (b) MEM, 10% FCS + 1 X 10-7M dexamethasone for 4 days 
prior to photography. Note enlargement, flattening, and 
Increased polygonal growth as compared to controls, (c) 
Appearance of large, multinucleated cells in dexamethasone- 
treated cultures 48 hours after plating. 
W7. 
FIG. 2. Effect of dexamethasono treatment on OVCA 433 CA 125 
expression. Immunohist ocliemlcal staining of (a) 
dexamethasone-t reated and fh) -untreated OVCA 433 cells 
fixed X 24 hours in }>a rn forma 1 dehyde demonstrates 
decreased expression of OC 123 cell surface binding sites by 
cells exhibiting dexametbasone-induced morphological 
alterations. (a) Note heterogeneity of staining within 
dexamethasone-treated monolayer. Smaller cells and 
cytoplasmic extensions stain most intensely while enlarged, 
polygonal cells (arrow) exhibil mostly diffuse, perintu lear 
staining. 
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FIG. 3. Immimolocalization of CA 12S in OVGA 433 ovarian 
carcinoma cells. Cells stainorl with OC 12'i using DAR/Ni 
ammonium sulfate substrate photographed with the aid of a 
video-enhanced differential interference camera system, fa) 
and (b) Two focal planes exliibited to demonstrate staining 
is predominantly restricted to cell surface membrane and 
cytoplasmic processes, (c) OVCA A33 cells stained as above 
except OC 125 primary incubation step ommited to demonstrate 
specificity of substrate react ion for OC 125 bound sites. 




FIG. 4. Inmninolocalization of CA 12S in OVCA A33 cells treated 
with 1 X 10-6M dexamethasoTie or cortisol. OVCA 433 cells 
stained for OC 125-bindiiig sites and photographed as 
described in FIG. 3. Cells exhibit stereotypic 
glucocorticoid-induced morphological alterations including 
enlargement, increased cytoplasmic; nuclear ratio, and 
polygonal growth. Note granular DAB/Ni immunoprecipitate is 
restricted to perinuclear region;(a) focal plane 1 tb) focal 
plane 2 with decreased cell surface staining for CA 125 
relative to untreated OVCA 433 cells in FTG. 3. (c) OVCA 433 
cells treated with the physiologic glucocorticoid, cortisol, 
display similar pattern of staining. 
'f 
Aksoriaaec 6O0am 
Pwys Coitrol vyea. lO-TH 10-811 lOOM lo-um 
1 J063 J058 iM9 547 J044 J047 
2 .113 J096 J097 .09? .105 .108 
3 .232 .196 J91 201 206 .214 
4 .300 .239 257 267 287 298 
5 .426 .291 255 281 .422 .420 
6 .602 J559 .575 508 -574 .438 
7 592 J583 597 .638 586 298 
Table 1.1. Glucocorticoid inhibition of OVCA 433 cell 
growth . OVCA 433 cells were freshly plated with 
dexamethasone in concentrations ranging from 10-6M to 10- 
lOM. Cell growth microcultiire assay results reported as 
Absorbance at 600 nm at 1-7 days post plating as described 
in Materials and Methods. 
los (AiMTiuM 600 am X 1000) 
105H i(mi 10-811 10^ W-lOll CoiCiol 
1 1.76 1.69 157 1.64 1.67 120 
2 1.98 1-99 129 2.02 253 2.05 
3 229 228 220 221 223 2-36 
4 2.38 2.41 2-43 2.46 2-47 2-49 
5 2.46 2.55 258 2.63 252 253 
6 2J75 2-76 2.78 2.76 254 2.78 
7 2-77 2.78 2.80 2.77 250 2.77 
Table 1.2. Logarithmic representation of glucocorticoid 
inhibition of OVCA 433 cell growth. Cell growth microciilture 
























FIG. 5. Dexamethasone-induced growth inhibition of 
cells. vs. day in culture. 
OVCA 433 
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FIG. 6. Dexamethasone-induced growth inhibition of 
cells. Log (AbsgQQj^j X 1000) vs. day in culture. 
OVCA 433 

FIG. 7. Effect of OC 125 on OVCA 433 cells vitro: Altered 
morphology and pattern of growth. OVCA 433 cells were plated 
in (a) MEM, 10% FCS or (b) MEM, 10% FCS + 30 ng/ml OC 125. 
Note dramatic cell enlargement, increased 
cytoplasmic:nuclear ratio, and neat, hexagonal array of 
nonoverlapping cells in (b). 
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FTG. 8. Specificity 
of OC 125 effect. 
OVCA 433 cells were 
incubated with (a) 
MEM, 10?<; PCS or MEM, 
10°^ PCS + (b) 10 
ng/ml nr 125, (c) 10 
ng/ml whole mouse 
IgG, fd) 10 ug/ml 
mouse IgGl Pc 
f ragmenI , or (e) 10 
ng/m) mouse IgG 
Kappa in MOPC 21 
ascites (specificity 
unknown). 
- k f'* 
FIG. 9. Specificity of OC 12S effect. OVCA 433 cells were 
plated in MEM, 10% FCS + 10 ng/ml (a) MAb anti-HCG ("beta 
fragment) and (b) MAb an1 i-i issue plasminogen art ivator 
without effect. 

FIG. 10. Specificity of OC 125 effect, (a) OVCA W cells and 
two alternate human ovarian carcinoma cel] lines,(b) Caov-3 
and (c) SK-OV-3, which do not express significant quantities 
of CA 125 were plated in MEM, 10% FCS + 10 ng/ml OC 125. 
Only OVCA 433 cells exhibit altered morphology. Littlefield 
previously demonstrated that OVCA 433 cells secrete "^lOOO 
U/ml CA 125 into the culture media while antigen is not 
detectable in supernatants harvested from Caov-3 and SK-nV-3 
cultures. 
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Table 2-1. OC 125 inhibition of OVCA 433 cell growth. OVCA 
433 cells were freshly plated with OC 125, anti-CA 125 MAb, 
at concentrations of 0, 0.1, 0.3, 1.0, 3.0, 10.0, and 30.0 
Tig/ml. Cell growth microculture assay results reported as 
Absorbance at 600nni +/- SE at 1-7 days post plating. 





OC125 INHIBITION OF OVCA 433 GROWTH 
N=7 LOG (1000 X Abs 600 nm) 
[0C12] DAY 1 DAY 2 DAY 3 OAY 4 DAY 5 DAY 6 DAY 7 
ug/ml 
0 1.80 2.05 2.36 2.49 2.63 2.78 2.77 
0.1 1.72 2.03 2.34 2.38' 2.60 2.81 2.81 
0.3 1.66 2.03 2.36 2.49 2.67 2.81 2.80 
1.0 
1 1.71 2.03 2.34 
2.49 2.66 2.76 2.75 
3.0 1.72 2.01 2.33 2.47 2.60 2.62 2.57 
10.0 1.68 1.98 2.27 2.39 2.50 1.04 1.15 
30.0 1.67 1.86 2.03 2.06 2.09 2.25 2.20 
Table 2.2. Logarithmic representation of OC 125-induced 
growth inhibition of OVCA 433. Cell growth microculture 
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FIG. 13. OVCA 433 cells freshly plated with 30 ng/ml OC 125 
after 4 days in culture begin to lift off p1 astir forming 
structures reminiscent of the lining epithelial r^11s of 
microcysts noted in serous cyst adenocarcinomas. 

APPENDIX I. 63 
ANTIGENS ASSOCIATED WITH HUMAN EPITHELIAL OVARIAN CARCINOMAS 
DEFINED BY MONOCLONAL ANTIBODIES 
ANTIGEN MONOCLONAL INVESTIGATORS 
ANTIBODY 
High-molecular-weight OC 125 Bast 




F 36/22* Croghan 
DF3* Sekine 
HMFG1,HMFG2 Epenetos 
200 kd protein 454C11 Frankel 
105 kd glycoprotein MF116 Mattes 
80 kd protein OC133 Miotti 
72 kd protein 791-T/36 De Groote 
70 kd protein WB12123 Knauf 
60 kd protein 2C8,2F7 Bhattacharya 
48 kd protein 4F4,7AiO Bhattacharya 
Low-molecular-weight NS 19-9* Koprowski 
glycolipids MOV-2* Tagliabue 
*Carbohydrate detenninants 
From Bast, R.C., Jr., and Knapp, R.C. The Emerging Role of 
Monoclonal Antibodies in the Clinical Management of 
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